<DOC>
	<DOCNO>NCT00709332</DOCNO>
	<brief_summary>The purpose study assess effect folic acid administration blood level breakdown product oral contraceptive ( OC ) [ 250 mcg NGM/35 mcg EE ] tablet .</brief_summary>
	<brief_title>A Drug Interaction Study Folic Acid Oral Contraceptive Tablets Containing Norgestimate ( NGM ) /Ethinyl Estradiol ( EE ) Healthy Women .</brief_title>
	<detailed_description>This open-label , randomize ( study drug assign chance ) , single-center , pharmacokinetic interaction study . Healthy adult woman meet prestudy eligibility criterion randomize 1 2 treatment group . The randomization balance use permuted block . Healthy volunteer Group 1 receive single oral dose 250 Âµg NGM/35 mcg EE ( 1 tablet ) Days 1 17 , 1 mg folic acid Days 4 18 . Healthy volunteer Group 2 receive single , oral 1 mg dose folic acid Days 1 17 , 1 tablet Days 2 17 . Serial blood sample collect healthy volunteer Days 1 17 dosing specify time 72 hour dose pharmacokinetic evaluation . Healthy volunteer confine overnight study unit Days -1 16 overnight fast least 8 hour dose Days 1 17 . Healthy volunteer remain confined study unit 24-hour blood sample collect Days 2 18 . Safety base incidence adverse event , change clinical laboratory value , vital sign , electrocardiogram , physical gynecological examination finding . The Sponsor prematurely terminate study 14 February 2005 error make study site healthy volunteer randomization , time blood draw , handle laboratory sample . As result error , pharmacokinetic sample collect analyzed , new study initiate ( NRGMON-CON-1006 ) . Due premature termination study , healthy volunteer receive 9 day therapy . Most healthy volunteer complete screening premature termination procedure . Oral contraceptive tablet ( 250 mcg NGM/35 mcg EE ) ; Folic acid tablet ( 1 mg ) . Group 1 : Single OC tablet Days 1 17 , 1 folic acid tablet Days 4 18 . Group 2 : Single folic acid tablet Days 1 17 , 1 OC tablet Days 2 17 . The study drug take 240 mL ( 8 oz ) water approximately 8:00 a.m . Healthy volunteer require fast minimum 8 hour dose Days 1 17 .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Healthy Nonpregnant Nonlactating Nonsmoking woman Weighing least 110 pound With regular menstrual cycle A body mass index 16 29.9 kg/m2 And hematocrit least 36 % History presence disorder commonly accept contraindication sex hormonal therapy include : thromboembolic disorder cerebral vascular coronary artery disease , chronic untreated hypertension , migraine , benign malignant liver tumor develop use OC Known suspect estrogendependent neoplasia Presence disorder commonly accept contraindication combine OC include : undiagnosed abnormal vaginal bleeding , neurovascular lesion eye serious visual disturbance , liver disease Intake multivitamin folic acidcontaining supplement within 30 day study admission Used steroid hormonecontaining intrauterine device within 3 month prior study admission Used medication know cytochrome P450 enzyme inducer inhibitor ( e.g. , St. John 's Wort , cimetidine rifampin ) , within 60 day dose .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Norgestimate</keyword>
	<keyword>Folic Acid</keyword>
	<keyword>Ortho-Cyclen</keyword>
	<keyword>Female contraception</keyword>
	<keyword>Ethinyl Estradiol</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Contraceptives , Oral</keyword>
</DOC>